Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.62 |
| ▸ | CA1 | P00915 | 4/20 | 0.62 |
| ▸ | CA2 | P00918 | 4/20 | 0.62 |
| ▸ | CA9 | Q16790 | 4/20 | 0.62 |
| ▸ | GAA | P10253 | 3/20 | 0.54 |
| ▸ | MMP8 | P22894 | 2/20 | 0.50 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9338686 | 0.91 | CA12 (0.54) | CA12CA1CA2CA9GAA | |
| SCHEMBL13381398 | 0.89 | CA12 (0.52) | CA12CA1CA2CA9GAA | |
| SCHEMBL30450762 | 0.87 | HPGD (0.64) | CA12CA1CA2CA9MMP8 | |
| SCHEMBL27631537 | 0.85 | GAA (0.54) | CA12CA1CA2CA9GAA | |
| SCHEMBL5783774 | 0.85 | CA12 (0.67) | CA12CA1CA2CA9GAA | |
| SCHEMBL655368 | 0.84 | ELANE (0.53) | CA12CA1CA2CA9GAA | |
| SCHEMBL6026706 | 0.84 | ELANE (0.53) | CA12CA1CA2CA9GAA | |
| SCHEMBL8031605 | 0.84 | ELANE (0.53) | CA12CA1CA2CA9GAA | |
| SCHEMBL6719959 | 0.82 | ALDH1A1 (0.64) | CA12CA1CA2CA9NPC1 | |
| SCHEMBL5329232 | 0.82 | GAA (0.51) | CA12CA1CA2CA9GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9566284-B2 | Agents and methods for treating ischemic and other diseases | NONO INC. (CA) | 2017-02-14 | — | — | US | disclosed |
| US-20140235619-A1 | AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES | NONO INC. (CA) | 2014-08-21 | — | — | US | disclosed |
| EP-2617711-A1 | Amino alcohol derivatives, salts thereof and immunosuppressive agents | Kyorin Pharmaceutical Co., Ltd. (JP) | 2013-07-24 | — | — | EP | disclosed |
| US-20110251182-A1 | AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES | NONO, INC. (CA) | 2011-10-13 | — | — | US | disclosed |
| US-7763752-B2 | Amino alcohol derivatives, salts thereof and immunosuppresive agents | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2010-07-27 | — | — | US | disclosed |
| US-20090156653-A1 | Amino alcohol derivatives, salts thereof and immunosuppresive agents | KOHNO YASUSHI | 2009-06-18 | — | — | US | disclosed |
| US-7482491-B2 | Amino alcohol derivative, addition salt thereof, and immunosuppressant | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2009-01-27 | — | — | US | disclosed |
| US-20060135622-A1 | Amino alcohol derivative, addition salt thereof, and immunosuppressant | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2006-06-22 | — | — | US | disclosed |
| CN-1238347-C | Heterocyclic derivatives | NIPPON SHINYAKU CO LTD (JP) | 2006-01-25 | — | — | CN | disclosed |
| EP-1548003-A1 | AMINO ALCOHOL DERIVATIVE, ADDITION SALT THEREOF, AND IMMUNOSUPPRESSANT | Kyorin Pharmaceutical Co., Ltd. (JP) | 2005-06-29 | — | — | EP | disclosed |
| CN-1430612-A | Hete rocyclic derivatives | NIPPON SHINYAKU CO LTD (JP) | 2003-07-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251182-A1 | AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES | TRPM7, TRPM8, TRPM6 | CA12 2437/4885CA1 695/4885CA2 208/4885 |
| US-20140235619-A1 | AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES | TRPM7, TRPM8, TRPM6 | CA12 2437/4885CA1 695/4885CA2 208/4885 |
| US-20060135622-A1 | Amino alcohol derivative, addition salt thereof, and immunosuppressant | AADAT, BCAT2, ADH1A | CA12 2799/4885CA1 3443/4885CA2 3601/4885 |
| US-20090156653-A1 | Amino alcohol derivatives, salts thereof and immunosuppresive agents | ADH1A, TPMT, AADAT | CA12 3811/4885CA1 4139/4885CA2 4319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.